Adebrelimab combined with SOX regimen · Oncology Adebrelimab is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with SOX chemotherapy (S-1 and oxaliplatin) for enhanced cytotoxic and immunological effects.
nab-paclitaxel，Cisplatin · Oncology nab-paclitaxel and cisplatin work together as a chemotherapy combination to disrupt microtubule dynamics and cause DNA cross-linking, respectively, leading to cancer cell death.